September 29, 2009
Breaking News at TheBody.com
News & Views Library
Change/Update Subscription

HIV VACCINE STUDY NEWS: THE MORNING AFTER


 The Reaction: HIV Community at Odds Over Study Results

The results of the RV144 "prime-boost" HIV vaccine study made a tremendous splash in mainstream news and social media last week. But do the data really hold up to the hype?

Some top HIV/AIDS organizations are urging the world not to jump to conclusions. "[I]t appears that the statistical significance [of the results] hangs on very few cases of HIV infection," said Treatment Action Group, which in a statement urged "caution in interpreting the findings until more detailed information is available."

Other organizations and members of the scientific community responded to the study results enthusiastically. However, none suggested that the study results signify that a fully effective HIV vaccine is right around the corner.


 The Context: More Information on This Study

Still trying to wrap your head around the major findings of this study? Visit TheBody.com's RV144 page for a range of articles and reactions on the RV144 trial and its results, including:


Additional news and analysis of this headline-grabbing development in HIV/AIDS research will continue to arrive over the upcoming days. Be sure to check back at TheBody.com for the latest!

Video Newsbreak: Tune in to the Latest in HIV/AIDS News

HIV/AIDS Video Newsbreak, September 22, 2009

In the latest edition of TheBody.com's informative news video, we discussed a new report card for the HIV drug industry, H1N1 (swine flu), a chance for you to donate your unused HIV meds to a great cause, and more!

Visit our HIV/AIDS Video Newsbreak page to find out how to add our videos to your own Web site or blog, or share it with others on Facebook, Twitter and elsewhere.